Menu Search
Equities

Remus Pharmaceuticals Ltd

REMUS:NSI

Remus Pharmaceuticals Ltd

Actions
  • Price (INR)2,399.95
  • Today's Change-45.00 / -1.84%
  • Shares traded900.00
  • 1 Year change+76.34%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 05:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Remus Pharmaceuticals Ltd grew revenues 371.94% from 450.27m to 2.12bn while net income improved 153.29% from 85.03m to 215.37m.
Gross margin22.67%
Net profit margin12.22%
Operating margin12.67%
Return on assets17.80%
Return on equity40.64%
Return on investment44.48%
More ▼

Cash flow in INRView more

In 2024, Remus Pharmaceuticals Ltd increased its cash reserves by 242.62%, or 190.26m. Cash Flow from Financing totalled 243.66m or 11.47% of revenues. In addition the company generated 36.02m in cash from operations while cash used for investing totalled 89.43m.
Cash flow per share47.41
Price/Cash flow per share54.11
Book value per share147.42
Tangible book value per share131.52
More ▼

Balance sheet in INRView more

Remus Pharmaceuticals Ltd has a Debt to Total Capital ratio of 9.97%, a lower figure than the previous year's 37.05%.
Current ratio1.40
Quick ratio1.12
Total debt/total equity0.133
Total debt/total capital0.0997
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 200.00% and 82.59%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)4.10%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.